552 related articles for article (PubMed ID: 22922056)
1. Nicotinamide phosphoribosyl-transferase/visfatin: a missing link between overweight/obesity and postmenopausal breast cancer? Potential preventive and therapeutic perspectives and challenges.
Dalamaga M
Med Hypotheses; 2012 Nov; 79(5):617-21. PubMed ID: 22922056
[TBL] [Abstract][Full Text] [Related]
2. The role of extracellular and intracellular Nicotinamide phosphoribosyl-transferase in cancer: Diagnostic and therapeutic perspectives and challenges.
Dalamaga M; Christodoulatos GS; Mantzoros CS
Metabolism; 2018 May; 82():72-87. PubMed ID: 29330025
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum visfatin/nicotinamide phosphoribosyl-transferase levels are associated with risk of postmenopausal breast cancer independently from adiponectin, leptin, and anthropometric and metabolic parameters.
Dalamaga M; Karmaniolas K; Papadavid E; Pelekanos N; Sotiropoulos G; Lekka A
Menopause; 2011 Nov; 18(11):1198-204. PubMed ID: 21712732
[TBL] [Abstract][Full Text] [Related]
4. The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids.
Chang YC; Chang TJ; Lee WJ; Chuang LM
Metabolism; 2010 Jan; 59(1):93-9. PubMed ID: 19765775
[TBL] [Abstract][Full Text] [Related]
5. Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease.
Moschen AR; Geiger S; Gerner R; Tilg H
Mutat Res; 2010 Aug; 690(1-2):95-101. PubMed ID: 19583971
[TBL] [Abstract][Full Text] [Related]
6. Nampt and its potential role in inflammation and type 2 diabetes.
Garten A; Petzold S; Schuster S; Körner A; Kratzsch J; Kiess W
Handb Exp Pharmacol; 2011; (203):147-64. PubMed ID: 21484571
[TBL] [Abstract][Full Text] [Related]
7. Retinol-binding protein 4 and nicotinamide phosphoribosyltransferase/visfatin in rat obesity models.
Mercader J; Granados N; Caimari A; Oliver P; Bonet ML; Palou A
Horm Metab Res; 2008 Jul; 40(7):467-72. PubMed ID: 18401839
[TBL] [Abstract][Full Text] [Related]
8. Hyperresistinemia is associated with postmenopausal breast cancer.
Dalamaga M; Karmaniolas K; Papadavid E; Pelekanos N; Sotiropoulos G; Lekka A
Menopause; 2013 Aug; 20(8):845-51. PubMed ID: 23481121
[TBL] [Abstract][Full Text] [Related]
9. The Role of Adipokines in Breast Cancer: Current Evidence and Perspectives.
Christodoulatos GS; Spyrou N; Kadillari J; Psallida S; Dalamaga M
Curr Obes Rep; 2019 Dec; 8(4):413-433. PubMed ID: 31637624
[TBL] [Abstract][Full Text] [Related]
10. Could serum visfatin be a potential biomarker for postmenopausal breast cancer?
Dalamaga M; Archondakis S; Sotiropoulos G; Karmaniolas K; Pelekanos N; Papadavid E; Lekka A
Maturitas; 2012 Mar; 71(3):301-8. PubMed ID: 22261365
[TBL] [Abstract][Full Text] [Related]
11. Visfatin is associated with lipid metabolic abnormalities in Lyon hypertensive rats.
Wang P; Bai C; Xu QY; Xu TY; Su DF; Sassard J; Miao CY
Clin Exp Pharmacol Physiol; 2010 Sep; 37(9):894-9. PubMed ID: 20456420
[TBL] [Abstract][Full Text] [Related]
12. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine.
Sommer G; Garten A; Petzold S; Beck-Sickinger AG; Blüher M; Stumvoll M; Fasshauer M
Clin Sci (Lond); 2008 Jul; 115(1):13-23. PubMed ID: 19016657
[TBL] [Abstract][Full Text] [Related]
13. Energy balance, physical activity, and cancer risk.
Fair AM; Montgomery K
Methods Mol Biol; 2009; 472():57-88. PubMed ID: 19107429
[TBL] [Abstract][Full Text] [Related]
14. Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis.
de Boer JF; Bahr MJ; Böker KH; Manns MP; Tietge UJ
Am J Physiol Gastrointest Liver Physiol; 2009 Feb; 296(2):G196-201. PubMed ID: 19074645
[TBL] [Abstract][Full Text] [Related]
15. Obesity, insulin resistance, adipocytokines and breast cancer: New biomarkers and attractive therapeutic targets.
Dalamaga M
World J Exp Med; 2013 Aug; 3(3):34-42. PubMed ID: 24520544
[TBL] [Abstract][Full Text] [Related]
16. Visfatin--a review.
Sonoli SS; Shivprasad S; Prasad CV; Patil AB; Desai PB; Somannavar MS
Eur Rev Med Pharmacol Sci; 2011 Jan; 15(1):9-14. PubMed ID: 21381495
[TBL] [Abstract][Full Text] [Related]
17. Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans.
Laudes M; Oberhauser F; Schulte DM; Freude S; Bilkovski R; Mauer J; Rappl G; Abken H; Hahn M; Schulz O; Krone W
Horm Metab Res; 2010 Apr; 42(4):268-73. PubMed ID: 20091460
[TBL] [Abstract][Full Text] [Related]
18. Visfatin/Nampt: an adipokine with cardiovascular impact.
Romacho T; Sánchez-Ferrer CF; Peiró C
Mediators Inflamm; 2013; 2013():946427. PubMed ID: 23843684
[TBL] [Abstract][Full Text] [Related]
19. Visfatin and its role in obesity development.
Stastny J; Bienertova-Vasku J; Vasku A
Diabetes Metab Syndr; 2012; 6(2):120-4. PubMed ID: 23153983
[TBL] [Abstract][Full Text] [Related]
20. Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders.
Moschen AR; Gerner RR; Tilg H
Curr Pharm Des; 2010 Jun; 16(17):1913-20. PubMed ID: 20370672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
